Ctla4 (Cd152, co-inhibitor of T-cell activity) and Il2ra (Cd25, involved in T-cell and B-cell activation and expressed on regulatory T cells) were also higher in AT1- and vehicle-LNs compared to MLL-LNs at day 3, further suggesting a higher T-cell activity in AT1- and vehicle-LNs compared to MLL-LNs early after tumor cell/vehicle injection. The gene discussed is KMT2A; the disease is neoplasm.